Cipla gets USFDA approval for HIV drug

Written by Medical Dialogues Bureau Published On 2018-01-29T13:40:57+05:30 | Updated On 29 Jan 2018 1:40 PM IST

New Delhi: Drug major Cipla said it has received final approval from the US health regulator for tenofovir disoproxil fumarate tablets, used to treat HIV-1 infections in adults.

Cipla in a BSE filing said it has received final approval from the United States Food and Drug Administration (USFDA) for tenofovir disoproxil fumarate tablets, 300 mg.

These tablets are AB-rated generic equivalents of Gilead Sciences' Viread Tablets, 300 mg, and are indicated in combination with other antiretroviral agents for the treatment of HIV -1 infection in adults and paediatric patients 12 years of age and older.

Citing IMS Health data, the company said Viread Tablets, 300mg, had US sales of approximately USD 725 million for the 12-month period ending November 2017.

antiretroviral agentsapprovalCiplagenericGilead SciencesHIV drugHIV-1IMS HealthTenofovir Disoproxil Fumarate TabletsUnited States Food and Drug AdministrationUSFDAViread Tablets

Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Medical Dialogues Bureau

Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here